Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:9/26/2008

IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it met with representatives of the Committee for Medicinal Products for Human Use (CHMP) and Secretariat of the European Medicines Agency (EMEA) on September 25th, following the CHMP's September meeting where CHMP considered the Company's Marketing Authorization Application (MAA) for mifamurtide (L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.

Based on discussions at that meeting, the Company has been invited to present to the CHMP Scientific Advisory Group on Oncology (SAG-O) and to the CHMP to review and address the remaining open issues in its MAA for L-MTP-PE. These meetings are scheduled to take place in November. The SAG-O is regularly convened at the request of the CHMP to provide independent advice on scientific/technical matters relating to oncology products under evaluation by the CHMP, or on any other scientific issue relevant to the work of the CHMP that relates to this area. The Company will provide SAG-O and CHMP information to address the remaining open issues in advance of these meetings.

"The European review of L-MTP-PE continues to progress," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We are pleased to report that, in response to the comprehensive information we submitted in advance of the September CHMP meeting, the CHMP has determined that the Children's Oncology Group's (COG) Phase 3 trial is compliant with Good Clinical Practices (GCP) and that the database from this pivotal study can be reliably used in the evaluation process of the MAA. We also r
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
10. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Australian biomarker ... important US trial of its MiStat™ prostate cancer screening ... (FDA) regulatory approval upon completion. Minomic,s proprietary ... the presence of a proprietary biomarker known as the ... of prostate cancer cells. Researchers at ...
(Date:9/18/2014)... , Sept. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to the position of  Senior Director of Clinical Development. ... Mr. James has established and led successful global clinical ... , to facilitate the clinical development of numerous ...
(Date:9/18/2014)... MILFORD, Mass. , Sept. 18, 2014 /PRNewswire/ ... developing novel therapeutics for the treatment of RNA ... National Institutes of Health (NIH) for animal testing ... multiple viral pathogens, classified as "Special Pathogens," against ... SB 9200, derived from Spring Bank,s ...
Breaking Medicine Technology:Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... United States Environmental Protection Agency (EPA) announced today a ... will be screened as part of EPA,s ToxCast initiative. ... this year, involves the application of extensive and diverse ... very pleased with our contributions to ToxCast to date, ...
... Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ) reports ... and Sun Pharma Global, Inc ("Sun Global") for a going ... more of their affiliates would acquire all of the outstanding ... Sun Global for a per share consideration of $4.75 in ...
Cached Medicine Technology:Odyssey Thera to Participate in Expanded EPA Initiative 2Caraco Receives Sun Pharma Proposal to Purchase All Outstanding Shares 2Caraco Receives Sun Pharma Proposal to Purchase All Outstanding Shares 3
(Date:9/18/2014)... Recently, WowBobble.com, the popular online supplier of funny ... to its product line. Moreover, all the company’s products ... customers can enjoy the special offer before September 29, 2014. ... prices ($12.5 for each bobblehead doll ). , ... bobbleheads. We want to make our interesting items available to ...
(Date:9/18/2014)... 18, 2014 Fit Body Boot Camp ... fitness business in the country and its popularity, as both ... to grow enormously in 2014. , The company’s annual ... taking place in Costa Mesa, CA on September 26 and ... conferences yet. Founder Bedros Keuilian, who is also considered the ...
(Date:9/18/2014)... A positive outlook on life can go far ... year, at the Weekend for Women Conference in Los Angeles, ... talk show host Mother Love will be speaking on embracing ... The always-funny Jo Anne Hart, aka Mother Love, has appeared ... widely acclaimed talk show on LATalkRadio.com, which airs weekdays from ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 How much ... That’s one of the factors contributing to the obesity ... constitutes a single serving and how to manage portion ... Control” presentation Oct. 3 at Humility House, 755 Ohltown ... Lackey will lead the informational discussion and answer questions ...
(Date:9/18/2014)... 2014 It is true that ... when building a successful brand or business online. ... has recently compared plenty of professional web hosting ... Arvixe and iPage are the best VPS hosting ... of web hosting. All-sized businesses or enterprises can ...
Breaking Medicine News(10 mins):Health News:Discounted Custom Bobbleheads Online For Sale At WowBobble.com 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3Health News:DiabetesSisters Showcases Radio Talk Show Host Mother Love at Weekend for Women Conference in Los Angeles 2Health News:HMHP Workshop Addresses Portion Control 2Health News:Best Cheap Hosting USA: GreenGeeks, Arvixe And iPage Are The Best Hosting Suppliers In 2014 2
... , , LOS ANGELES, Dec. ... lives. In a decade, like so many in the preceding century ... been uncounted lives saved . Narconon is certainly ... year out, to save lives. We congratulate the selfless staffs of ...
... working on genetic puzzle to try to save the mammals ... a better understanding of an outbreak of cancerous tumors that ... new report. , Devil facial tumor disease, a kind of ... other physical contact, is one of only two types of ...
... that condition is unavoidable, expert says , THURSDAY, Dec. 31 ... stave off frailty among the elderly. , The notion is ... old that tracked the activities of over 1,000 physically active ... reasonably high-functioning. , Those who spent time volunteering were ...
... ... Online Marketing. We,ve seen a restaurant chain launched promotion that sold out in 90 minutes ... ... downturn of 2009 and closed, there were a handful that took the path less beaten ...
... , WARMINSTER, Pa., Dec. 31 ... leading home gardening company, reports brisk sales for its recently launched, ... containing different varieties for home gardeners who want to make New ... ) , The giant seedpack contains varieties of vegetables and flowers ...
... 31 The following is a statement of Matthew L. ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) , North Carolina on January 2 will ... first major tobacco-growing state to implement a statewide smoke-free law ... will protect the right of North Carolinians to breathe clean ...
Cached Medicine News:Health News:Narconon Salutes Its 1,200 Staff Worldwide on 13,000 Lives Saved This Last Decade 2Health News:Narconon Salutes Its 1,200 Staff Worldwide on 13,000 Lives Saved This Last Decade 3Health News:Clues to Cancer That Could Wipe Out Tasmanian Devils 2Health News:Volunteering May Keep Elderly Stronger 2Health News:Volunteering May Keep Elderly Stronger 3Health News:Small Businesses In Singapore Outmarkets & Outperforms Bigger Players in Tough Economy With Online Marketing 2Health News:New Year's Resolution Garden Growing Sales for Burpee 2Health News:North Carolina Goes Smoke-Free on Jan. 2 in Historic Step for Health 2Health News:North Carolina Goes Smoke-Free on Jan. 2 in Historic Step for Health 3
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
For primary and revision cases...
Medicine Products: